NR507 Advanced Pathophysiology Midterm Study Guide

Alterations in Immunity and Inflammation (Week 1)

• Hypersensitivity Reactions:

  • Type I (Immediate / $IgE$-Mediated): Initial antigen exposure induces $CD4^+$ $Th2$ cells to secrete $IL-4$ and $IL-13$, prompting class switching to $IgE$, which anchors to mast cell/basophil $Fc\epsilon RI$ receptors. Re-exposure cross-links $IgE$, mobilizing calcium and triggering immediate degranulation of histamine, proteases, leukotrienes ($LTC_4$, $LTD_4$, $LTE_4$), and prostaglandins ($PGD_2$). Results in arteriolar dilation, increased vascular permeability, smooth muscle spasm (bronchospasm), and pruritus.

  • Prototype: Anaphylaxis, allergic asthma, urticaria.

  • Management: Immediate intramuscular epinephrine ($1:1000$ dilution, $0.3$ to $0.5\,\text{mg}$ in adults) into the anterolateral thigh to promote alpha-1 vasoconstriction and beta-2 bronchodilation; supportive crystalloids, antihistamines, and systemic corticosteroids.

  • Type II (Tissue-Specific / Cytotoxic): Mediated by circulating $IgG$ or $IgM$ reacting with cell-surface or extracellular matrix antigens. Pathology occurs via complement-dependent lysis ($C5b-C9$ membrane attack complex), phagocytosis via opsonization ($C3b$, $Fc\gamma$), antibody-dependent cellular cytotoxicity ($ADCC$ via $NK$ cells), or receptor signaling blockade/stimulation (e.g., TSH receptor stimulation in Graves disease, acetylcholine receptor downregulation in myasthenia gravis).

  • Prototypes: Autoimmune Hemolytic Anemia ($AIHA$), Goodpasture syndrome, Immune Thrombocytopenia ($ITP$), Myasthenia Gravis.

  • Management: Corticosteroids, therapeutic plasma exchange (plasmapheresis), intravenous immunoglobulin ($IVIG$), and rituximab.

  • Type III (Immune Complex-Mediated): Soluble antigen-antibody ($IgG$/$IgM$) complexes form in the circulation and deposit in microvascular beds with high filtration pressure (glomeruli, synovium, skin). Deposited complexes activate complement ($C3a$, $C5a$), recruiting polymorphonuclear neutrophils ($PMNs$). Attempted phagocytosis ("frustrated phagocytosis") releases elastase and reactive oxygen species, driving acute necrotizing vasculitis.

  • Prototypes: Systemic Lupus Erythematosus ($SLE$), Post-Streptococcal Glomerulonephritis ($PSGN$), Serum Sickness.

  • Management: Discontinuation of antigen, $NSAIDs$, systemic corticosteroids, and cyclophosphamide.

  • Type IV (Cell-Mediated / Delayed-Type): Antibody-independent; driven by antigen-sensitized T-lymphocytes peaking $24$ to $72\,\text{hours}$ post-exposure. $Th1$ cells secrete $IFN-\gamma$ to activate tissue macrophages into epithelioid/giant cells; $Th17$ cells recruit neutrophils; $CD8^+$ cytotoxic T lymphocytes ($CTLs$) directly induce target apoptosis via perforin/granzyme and Fas/FasL.

  • Prototypes: Allergic Contact Dermatitis (poison ivy, nickel), Tuberculin skin test ($PPD$), chronic graft rejection.

  • Management: Trigger elimination, topical high-potency corticosteroids, or extended oral prednisone taper.

• Human Immunodeficiency Virus ($HIV$):

  • Mechanism: Enveloped single-stranded retrovirus ($ssRNA$). Viral envelope gp120 binds host $CD4$ and co-receptors ($CCR5$ or $CXCR4$); gp41 mediates fusion. Viral reverse transcriptase synthesizes $cDNA$, integrase incorporates it into host DNA (provirus), and protease matures budding virions.

  • $CD4^+$ Depletion: Direct viral cytolysis, caspase-1-dependent pyroptosis of bystander T cells, $CD8^+$ CTL-mediated destruction, and lymphoid architectural collapse.

  • AIDS Definition: Documented absolute $CD4^+$ T-cell count $< 200\,\text{cells}/\mu\text{L}$ (or $< 14\%$ total lymphocytes) or presentation with an AIDS-defining illness (e.g., Pneumocystis jirovecii pneumonia, Kaposi sarcoma, cryptococcal meningitis).

• Systemic Lupus Erythematosus ($SLE$):

  • Pathophysiology: Loss of self-tolerance to nuclear antigens coupled with defective apoptotic debris clearance. Uncleared nuclear fragments stimulate plasmacytoid dendritic cells via $TLR7$ and $TLR9$ to produce $IFN-\alpha$. Hyperactive B cells produce antinuclear autoantibodies ($ANAs$). Circulating immune complexes deposit in tissues (Type III), while direct autoantibody-mediated cytopenias manifest (Type II).

  • Diagnostic Autoantibodies: High-sensitivity $ANA$ ($> 95\%$; screening standard); disease-specific anti-dsDNA (correlates with lupus nephritis activity); pathognomonic anti-Smith ($\text{anti-Sm}$); antiphospholipid antibodies (Lupus Anticoagulant, Anticardiolipin; associated with arterial/venous thrombosis and recurrent fetal loss). Laboratory findings show consumed/low complement ($C3$, $C4$) and elevated $ESR$.

  • Clinical Features: Malar rash (nasolabial sparing), photosensitivity, painless oral ulcers, non-erosive polyarthritis, pleuropericarditis, lupus nephritis (proteinuria $> 0.5\,\text{g}/24\,\text{hours}$, cellular casts), and Coombs-positive hemolytic anemia.

  • Management: Baseline hydroxychloroquine for all patients (requires routine retinal screening); $NSAIDs$ or low-dose prednisone for mild flares; pulse-dose methylprednisolone combined with cyclophosphamide or mycophenolate mofetil ($MMF$) for severe/renal manifestations.

• Alloimmunity & Immunodeficiency:

  • Alloimmunity: Immune reaction against non-self antigens from the same species. Manifests as hemolytic transfusion reactions, Hemolytic Disease of the Fetus and Newborn ($HDFN$ via maternal anti-Rh $IgG$), solid organ transplant rejection (hyperacute via pre-formed antibodies, acute via $CD8^+$ T cells, chronic via fibrointimal vascular obliteration), and Graft-Versus-Host Disease ($GVHD$ via donor T cells attacking recipient skin, liver, and gut).

  • Primary vs. Secondary Immunodeficiency: Primary stems from intrinsic genetic defects (B-cell defects like X-linked Bruton agammaglobulinemia; T-cell defects like DiGeorge syndrome; combined defects like $SCID$; phagocytic defects like Chronic Granulomatous Disease). Secondary stems from extrinsic factors: protein-calorie malnutrition, systemic chemotherapy/corticosteroids, HIV infection, chronic kidney disease, or splenectomy.

  • Common Variable Immunodeficiency ($CVID$): B cells fail to differentiate into antibody-secreting plasma cells. Characterized by low serum $IgG$ ($< 300\,\text{mg/dL}$), low $IgA$/$IgM$, and poor response to vaccines. Presents in early adulthood with recurrent bacterial sinopulmonary infections, Giardia enteropathy, bronchiectasis, and autoimmune cytopenias. Managed with lifelong $IVIG$/$SCIG$.

Hematological Pathologies (Week 2)

• Classification of Anemias by Mean Corpuscular Volume ($MCV$):

  • Microcytic ($\text{MCV} < 80\,\text{fL}$): Defective heme or globin synthesis forces excess precursor mitotic divisions.

  • Etiologies: Iron Deficiency Anemia ($IDA$), Thalassemia, Sideroblastic Anemia, late-stage Anemia of Chronic Disease ($ACD$).

  • Macrocytic ($\text{MCV} > 100\,\text{fL}$):

  • Megaloblastic: Defective DNA synthesis arrests cellular division while cytoplasmic maturation persists (nuclear-cytoplasmic dyssynchrony), causing hypersegmented neutrophils and macro-ovalocytes. Caused by Vitamin B-12 and Folate deficiencies.

  • Non-Megaloblastic: Normal DNA synthesis without hypersegmented neutrophils. Caused by liver disease, alcohol use disorder, reticulocytosis, and hypothyroidism.

  • Normocytic ($\text{MCV} = 80$ to $100\,\text{fL}$):

  • Hyperproliferative (Reticulocyte Production Index $\text{RPI} > 2\%$): Acute blood loss or active hemolysis (erythrocyte lifespan shortened from normal $120$ days to $< 20$ days).

  • Hypoproliferative ($\text{RPI} < 2\%$): Bone marrow aplasia, early nutritional deficiency, or absolute erythropoietin deficiency from Chronic Kidney Disease ($CKD$).

• Pathophysiology of Specific Anemias:

  • Anemia of Chronic Disease ($ACD$): Sustained systemic inflammation elevates Interleukin-6 ($IL-6$), prompting hepatic production of hepcidin. Hepcidin binds, internalizes, and degrades ferroportin-1 on enterocytes and macrophages, trapping iron within storage pools and preventing erythroid access (iron-restricted erythropoiesis).

  • Folate vs. Vitamin B-12 Deficiency:

  • Folate: Modest hepatic stores ($2$ to $4$ months). Elevates homocysteine, but methylmalonic acid ($MMA$) is normal. No neurological defects.

  • Vitamin B-12: Depleted stores take $3$ to $5$ years. Elevated homocysteine AND elevated $MMA$. Causes subacute combined degeneration (dorsal and lateral column demyelination) and is linked to Pernicious Anemia (anti-intrinsic factor autoantibodies).

  • Sickle Cell Anemia: Autosomal recessive $A \rightarrow T$ point mutation on the beta-globin gene (HBB), substituting nonpolar valine for polar glutamic acid ($\text{Glu} \rightarrow \text{Val}$) at position $6$, forming Hemoglobin S ($HbS$). Deoxygenation, acidosis, and dehydration cause $HbS$ crystallization into rigid polymers, sickling the cell. Causes microvascular vaso-occlusion, severe ischemic pain crises, extravascular hemolysis ($10$ to $20$ day cell survival), and auto-infarction of the spleen (functional asplenia by age $3$ to $5$ years, increasing encapsulated sepsis risk).

  • Beta-Thalassemia Major: Homozygous deletion/mutation in beta-globin chains creates an excess of unpaired alpha-globin chains that aggregate into toxic intracellular inclusions. Leads to severe ineffective erythropoiesis and extravascular hemolysis. Massive compensatory erythropoietin ($EPO$) drives profound bone marrow expansion ("chipmunk facies", "hair-on-end" skull radiographs), hepatosplenomegaly, and growth failure. Managed with biweekly/monthly packed red blood cell ($PRBC$) transfusions paired with systemic iron chelation (deferasirox, deferiprone, deferoxamine) to prevent fatal secondary hemochromatosis.

• Erythropoietin ($EPO$) & Diagnostics:

  • EPO Role: Synthesized by renal peritubular fibroblasts in response to Hypoxia-Inducible Factor ($HIF-1\alpha$) stabilization under low $PO_2$. Stimulates bone marrow erythroid progenitor ($CFU-E$) survival via the $JAK2/STAT5$ pathway.

  • Diagnostic Profiles:

  • IDA: Serum ferritin $< 30\,\text{ng/mL}$, low serum iron, high Total Iron-Binding Capacity ($\text{TIBC} > 400\,\mu\text{g/dL}$), transferrin saturation $< 16\%$, elevated red cell distribution width ($\text{RDW} > 15\%$).

  • Hemolytic Markers: Elevated $LDH$, high indirect bilirubin, positive Direct Coombs test, and severely decreased/absent haptoglobin.

  • Live Attenuated Vaccines: Contain replicating organisms; strictly contraindicated in immunocompromised patients (e.g., severe congenital immunodeficiencies, active chemotherapy, advanced HIV with $CD4^+ < 200\,\text{cells}/\mu\text{L}$, high-dose prednisone $\ge 20\,\text{mg/day}$ for $\ge 2$ weeks) due to risk of unchecked viral dissemination and life-threatening vaccine-strain infection.

Cardiovascular Pathologies (Week 2)

• Coronary Artery Disease ($CAD$) & Atherosclerosis:

  • Pathophysiology: Endothelial injury (hypertension, smoking, diabetes) increases vascular permeability and expression of adhesion molecules ($VCAM-1$, $ICAM-1$). Circulating low-density lipoproteins ($LDL$) invade the intima and undergo oxidation ($oxLDL$). Infiltrating monocytes engulf $oxLDL$ via scavenger receptors ($CD36$), transforming into foam cells that form fatty streaks. Smooth muscle cells migrate from media to intima, depositing collagen to form a fibrous cap over a necrotic lipid core. Macrophage-derived matrix metalloproteinases ($MMPs$) degrade the cap, predisposing it to rupture, platelet thrombosis, and acute coronary syndromes.

  • Lipid Profiles & Ranges:

  • Total Cholesterol: Normal $< 200\,\text{mg/dL}$; High $\ge 240\,\text{mg/dL}$.

  • LDL-C: Optimal $< 100\,\text{mg/dL}$ ($< 70\,\text{mg/dL}$ for very high-risk cardiovascular patients); High $160$ to $189\,\text{mg/dL}$; Very High $\ge 190\,\text{mg/dL}$.

  • HDL-C: Cardioprotective $\ge 60\,\text{mg/dL}$; High-risk/Low $< 40\,\text{mg/dL}$ (men), $< 50\,\text{mg/dL}$ (women). Mediates Reverse Cholesterol Transport ($RCT$) from peripheral tissues back to the liver via $ABCA1$ and $ApoA-I$.

  • Triglycerides: Normal $< 150\,\text{mg/dL}$; Severe hypertriglyceridemia ($\ge 500\,\text{mg/dL}$) elevates acute pancreatitis risk.

  • Dyslipidemia Causes: Primary includes Familial Hypercholesterolemia (mutations in LDLR, APOB, or PCSK9 gain-of-function). Secondary includes uncontrolled diabetes, hypothyroidism (downregulated hepatic LDL receptors), nephrotic syndrome, and cholestatic liver disease.

• Heart Failure ($HF$):

  • Left-Sided Heart Failure ($LHF$):

  • HFrEF (Systolic): Ejection Fraction $\text{EF} \le 40\%$. Deficient inotropy, eccentric remodeling, and chamber dilation impair forward stroke volume.

  • HFpEF (Diastolic): $\text{EF} \ge 50\%$. Ventricular concentric hypertrophy and stiffening elevate left ventricular end-diastolic pressure ($LVEDP$) despite normal chamber dimensions.

  • Retrograde/Forward Hemodynamics: Elevated $LVEDP$ elevates left atrial pressure, increasing pulmonary venous hydrostatic pressure. When hydrostatic pressure exceeds oncotic pressure ($> 20$ to $25\,\text{mmHg}$), pulmonary edema develops.

  • Signs & Sounds: Dyspnea, orthopnea, Paroxysmal Nocturnal Dyspnea ($PND$), bibasilar crackles, and laterally displaced $PMI$. Auscultation reveals $S_3$ (ventricular gallop; rapid filling into a volume-overloaded, compliant chamber in HFrEF) or $S_4$ (atrial gallop; atrial contraction against a stiff, non-compliant wall in HFpEF/hypertension).

  • Right-Sided Heart Failure ($RHF$):

  • Mechanisms: Most commonly caused secondary to LHF. Isolated RHF (cor pulmonale) results from pulmonary parenchymal or vascular disease. Systemic venous congestion elevates venous pressures.

  • Signs: Jugular Venous Distension ($\text{JVD} > 3$ to $4\,\text{cm}$), positive hepatojugular reflux, hepatomegaly, ascites, and dependent peripheral pitting edema.

  • ACC/AHA Stages & Pharmacotherapy:

  • Stage A: High risk without structural damage or symptoms (control lifestyle/metabolic risks).

  • Stage B: Asymptomatic structural disease (prior MI, reduced EF). Treat with ACEI/ARB and evidence-based beta-blockers (carvedilol, bisoprolol, metoprolol succinate).

  • Stage C: Structural disease with current/prior symptoms. Guideline-Directed Medical Therapy (GDMT Four Pillars):

    1. $ARNI$: Sacubitril/Valsartan (requires $36\,\text{hour}$ washout from ACEIs) or ACEI/ARB.

    2. Evidence-Based Beta-Blocker: Carvedilol, Metoprolol Succinate, or Bisoprolol.

    3. Mineralocorticoid Receptor Antagonist ($MRA$): Spironolactone or Eplerenone (monitor potassium and renal function).

    4. $SGLT2$ Inhibitor: Dapagliflozin or Empagliflozin.

    • Loop Diuretics: (Furosemide) added to achieve and maintain euvolemia.

  • Stage D: Advanced, refractory HF requiring advanced circulatory support ($LVAD$), inotropes, transplant, or hospice.

  • NYHA Functional Classes: Class I (no functional limitation); Class II (slight limitation, dyspnea with ordinary activity); Class III (marked limitation, comfortable only at rest); Class IV (symptoms present at rest).

• Valvular Disorders:

  • Aortic Stenosis ($AS$): Narrowing of aortic valve area ($< 1.0\,\text{cm}^2$), resulting in left ventricular concentric hypertrophy. Harsh crescendo-decrescendo systolic murmur at the right second intercostal space radiating to carotids; weak, slow pulse (pulsus parvus et tardus) and $S_4$. Caused by calcific degeneration or bicuspid valve.

  • Aortic Regurgitation ($AR$): Diastolic backward leak into LV causing eccentric hypertrophy and wide pulse pressures. High-pitched, blowing decrescendo early diastolic murmur at the left third/fourth intercostal space; bounding Corrigan water-hammer pulses.

  • Mitral Stenosis ($MS$): Inflow obstruction elevating left atrial pressure, causing left atrial enlargement and atrial fibrillation. Low-pitched, rumbling mid-diastolic murmur with an opening snap ($OS$) at the apex. Caused predominantly by Rheumatic Heart Disease.

  • Mitral Regurgitation ($MR$): Systolic retrograde jet from LV into LA causing volume overload and dilation. Blowing holosystolic murmur radiating to the left axilla with an apical $S_3$. Caused by mitral valve prolapse, infective endocarditis, or papillary muscle ischemia/rupture.

Pulmonary Pathologies (Week 3)

• Mechanics of Breathing & PFT Patterns:

  • Mechanics: Inspiration is active, mediated by diaphragm ($C3-C5$) and external intercostals expanding thoracic volume. Intrapleural pressure drops from $-5\,\text{cm } H_2O$ to $-8\,\text{cm } H_2O$, lowering alveolar pressure ($P_{\text{alv}} \approx -1\,\text{cm } H_2O$) relative to atmosphere. Quiet expiration is passive via tissue elastic recoil; forced expiration is active using abdominal wall and internal intercostal muscles.

  • Obstructive Pattern: Limitation of expiratory airflow. Hallmark: Reduced $\text{FEV}_1 / \text{FVC} < 0.70$, low $\text{FEV}_1$ ($< 80\%$ predicted), with increased Residual Volume ($\text{RV} > 120\%$) and Total Lung Capacity ($\text{TLC}$) from air trapping. Reversibility defined as post-bronchodilator increase in $\text{FEV}_1$ or $\text{FVC}$ by $\ge 12\%$ and $\ge 200\,\text{mL}$.

  • Restrictive Pattern: Impaired lung expansion and decreased compliance. Hallmark: Preserved/elevated $\text{FEV}_1 / \text{FVC} \ge 0.70$, with reduced $\text{TLC} < 80\%$ predicted and proportional decreases in $\text{FEV}_1$ and $\text{FVC}$. Intrinsic restriction (pulmonary fibrosis) demonstrates reduced carbon monoxide diffusing capacity ($DLCO$), whereas extrinsic restriction (kyphoscoliosis, myasthenia gravis) features normal $DLCO$.

• Chronic Obstructive Pulmonary Disease ($COPD$):

  • Chronic Bronchitis: Productive cough for $\ge 3$ consecutive months in $\ge 2$ consecutive years. Mucus gland hyperplasia, goblet cell metaplasia, and elevated Reid Index ($> 0.5$). Presents with chronic productive cough, cyanosis, and rhonchi ("Blue Bloaters"). Chronic hypoxemia triggers hypoxic pulmonary vasoconstriction, leading to pulmonary hypertension, cor pulmonale, and secondary polycythemia.

  • Emphysema: Permanent distal airspace enlargement with alveolar wall destruction and loss of elastic recoil/radial traction.

  • Centriacinar: Proximal/central acinus affected (upper lobes); linked to cigarette smoking.

  • Panacinar: Entire acinus destroyed (lower bases); classic for homozygous Alpha-1 Antitrypsin ($AAT$) deficiency ($PiZZ$ genotype).

  • Paraseptal: Distal acinus and subpleural space involved; predisposing factor for apical bleb rupture and spontaneous pneumothorax in young adults.

  • Presentation: Debilitating dyspnea, barrel chest ($1:1$ AP diameter), pursed-lip breathing, tripod posturing, weight loss/cachexia, and hyperresonance ("Pink Puffers").

  • COPD Management: Smoking cessation (slows $\text{FEV}_1$ decline); inhaled $LAMA$ and/or $LABA$; inhaled corticosteroids ($ICS$) for frequent exacerbations/eosinophils; long-term oxygen therapy ($LTOT$ for $\ge 15\,\text{hours/day}$ if $\text{PaO}_2 \le 55\,\text{mmHg}$ or $\text{SpO}_2 \le 88\%$).

• Asthma:

  • Pathophysiology: Chronic inflammatory disorder driven by $Th2$-mediated Type I hypersensitivity. Early phase ($10$ to $30\,\text{minutes}$) involves mast cell degranulation (histamine, leukotrienes) inducing bronchospasm and mucosal edema. Late phase ($4$ to $8\,\text{hours}$) is maintained by recruited eosinophils releasing Major Basic Protein ($MBP$) and cationic proteins, stripping airway epithelium and exposing sensory nerves. Airway remodeling features subepithelial collagen deposition and smooth muscle hypertrophy.

  • Acute Exacerbation Management: Short-Acting Beta-2 Agonists ($SABA$; albuterol) paired with Short-Acting Muscarinic Antagonists ($SAMA$; ipratropium) and systemic corticosteroids (prednisone or methylprednisolone). Intravenous magnesium sulfate ($2\,\text{g}$) used for severe, refractory bronchospasm.

  • Red Flags for Imminent Respiratory Failure: Absence of wheezing ("silent chest"), paradoxically normalized or rising arterial carbon dioxide ($\text{PaCO}_2 \ge 42\,\text{mmHg}$ indicating respiratory muscle fatigue), confusion, and thoracoabdominal exhaustion.

  • Patient Education: Follow a written Asthma Action Plan (Green $\ge 80\%$, Yellow $50$ to $79\%$, Red $< 50\%$ of personal best peak expiratory flow). Avoid triggers (dust mites, smoke, NSAIDs in Samter triad); use a spacer with MDIs; rinse mouth and spit after inhaled corticosteroids to prevent oral candidiasis.

• Interstitial Lung Disease ($ILD$) / Pulmonary Fibrosis:

  • Repeated alveolar micro-injuries lead to dysfunctional type II pneumocyte repair and excess Transforming Growth Factor-beta ($TGF-\beta$) secretion. Promotes myofibroblast expansion and dense interstitial collagen deposition (Type I/III), obliterating capillaries and producing "honeycomb lung" (Usual Interstitial Pneumonia pattern).

  • Physical Exam: Bilateral, dry, late-inspiratory "Velcro-like" crackles that do not clear with cough; digital clubbing (hypertrophic osteoarthropathy); signs of cor pulmonale in late stages.

Urinary System and Renal Pathologies (Week 4)

• Urinary Tract Infections ($UTIs$) & Pyelonephritis:

  • Pathophysiology: Ascending colonizing flora. Uropathogenic Escherichia coli ($UPEC$) accounts for $75\%$ to $90\%$ of community UTIs, utilizing Type 1 pili (umbrella cell invasion) and P-fimbriae (binding renal tubular cells against urinary flow).

  • Cystitis: Dysuria, urgency, frequency, and suprapubic pain. Absence of systemic signs (fever, flank pain). Urinalysis demonstrates pyuria, positive leukocyte esterase, and positive nitrites.

  • Complicated UTI: Occurs in males, pregnant patients, patients with anatomic/functional urinary tract abnormalities ($BPH$, stones, reflux), immunosuppressed hosts, or patients with indwelling catheters.

  • Acute Pyelonephritis: Ascending parenchymal/calyceal suppurative infection. Triad: High spiking fever, severe costovertebral angle ($CVA$) tenderness, and nausea/vomiting. Urinalysis reveals pathognomonic White Blood Cell (WBC) Casts, verifying renal parenchymal origin.

• Benign Prostatic Hyperplasia ($BPH$):

  • Non-malignant hyperplasia of prostatic stromal and epithelial cells localized strictly to the periurethral and Transition Zone (prostate cancer arises primarily in the peripheral zone). Driven by intraprostatic Dihydrotestosterone ($DHT$), converted from testosterone by 5-alpha reductase Type 2.

  • Symptoms: Obstructive (hesitancy, weak stream, intermittency, straining, post-void dribbling) and irritative (nocturia, frequency, urgency).

  • Treatment: Alpha-1 adrenergic receptor antagonists (tamsulosin) relax prostatic smooth muscle tone rapidly; 5-alpha reductase inhibitors (finasteride, dutasteride) block DHT, shrinking static prostate volume by $20\%$ to $25\%$ over $6$ to $12$ months (lowers baseline $PSA$ by $50\%$); transurethral resection of the prostate ($TURP$) for refractory obstruction.

• Renal Calculi (Nephrolithiasis):

  • Driven by urinary solute supersaturation, crystal nucleation, aggregation on Randall plaques, and deficiency of inhibitors (hypocitraturia).

  • Types:

  • Calcium Oxalate/Phosphate ($75\%$ to $80\%$): Radiopaque; hypercalciuria, hyperoxaluria, hypocitraturia.

  • Struvite ($10\%$ to $15\%$): Magnesium ammonium phosphate. Caused by urease-producing bacteria (Proteus mirabilis) converting urea to ammonia in alkaline urine (pH $> 7.2$); forms staghorn calculi.

  • Uric Acid ($5\%$ to $10\%$): Radiolucent on plain X-rays; forms in persistently acidic urine (pH $< 5.5$) and states of hyperuricosuria (gout, tumor lysis).

  • Cystine ($< 1\%$): Hexagonal crystals; autosomal recessive proximal tubular amino acid transport defect.

  • Presentation: Acute, excruciating, spasmodic renal colic radiating from the CVA along the ureter to the groin/scrotum/labia, paired with micro/gross hematuria and motor restlessness.

• Urinary Incontinence:

  • Urge Incontinence: Detrusor muscle overactivity producing sudden, uninhibited contractions and an uncontrollable desire to void; associated with neurologic insults, local bladder irritation, and advanced age.

  • Functional Incontinence: Involuntary loss of urine despite normal lower urinary tract mechanisms, caused by physical, cognitive, or environmental barriers (mobility deficits, dementia, restraints).

• Acute Kidney Injury ($AKI$):

  • Prerenal AKI: Transient hypoperfusion with intact parenchymal function. Compensatory efferent constriction (Angiotensin II) and afferent dilation (prostaglandins). Laboratory markers: Urine Osmolality $> 500\,\text{mOsm/kg}$, Urine Sodium $< 20\,\text{mEq/L}$, Fractional Excretion of Sodium $\text{FENa} < 1\%$, and $\text{BUN} / \text{Cr} > 20:1$. Treated with crystalloid volume restoration.

  • Intrinsic AKI (Acute Tubular Necrosis [$ATN$]): Direct parenchymal injury from prolonged ischemia or nephrotoxins (aminoglycosides, radiocontrast media, myoglobin). Loss of epithelial polarity, shedding of necrotic brush border, and luminal obstruction. Laboratory markers: Urine Osmolality $< 350\,\text{mOsm/kg}$, Urine Sodium $> 40\,\text{mEq/L}$, $\text{FENa} > 2\%$, $\text{BUN} / \text{Cr} \approx 10:1$ to $15:1$, and pathognomonic "Muddy Brown" Granular Casts.

  • Postrenal AKI: Mechanical urinary outflow obstruction ($BPH$, bilateral calculi) transmitting retrograde pressure that opposes glomerular filtration pressure.

  • Indications for Emergent Dialysis (AEIOU):

  • Acidosis: Refractory metabolic acidosis ($\text{pH} < 7.1$).

  • Electrolytes: Severe hyperkalemia ($K^+ > 6.5\,\text{mEq/L}$ or malignant ECG changes).

  • Ingestions: Toxic dialyzable substances (lithium, methanol, salicylates, ethylene glycol).

  • Overload: Refractory volume overload and pulmonary edema unresponsive to diuretics.

  • Uremia: Uremic pericarditis (friction rub), encephalopathy (asterixis), or bleeding diathesis.

• Chronic Kidney Disease ($CKD$) & Complications:

  • Definition: Kidney damage or $\text{GFR} < 60\,\text{mL/min}/1.73\,\text{m}^2$ for $\ge 3$ months. Renal ultrasound shows bilaterally shrunken kidneys with thinned cortices.

  • Stages: Stage 1 ($\text{eGFR} \ge 90\,\text{mL/min}/1.73\,\text{m}^2$); Stage 2 ($60$ to $89$); Stage 3a ($45$ to $59$); Stage 3b ($30$ to $44$); Stage 4 ($15$ to $29$; preparation for replacement); Stage 5 / ESRD ($< 15$; requires dialysis or transplant).

  • Azotemia vs. Uremia: Azotemia is the isolated biochemical elevation of BUN and creatinine. Uremic Syndrome represents the multi-system clinical toxic state (encephalopathy, asterixis, pericarditis, platelet dysfunction with bleeding diathesis, uremic frost, pruritus, uremic fetor, and high anion gap metabolic acidosis).

  • Renal Osteodystrophy & Vitamin D: Impaired proximal tubular 1-alpha-hydroxylase decreases active calcitriol ($1,25-(OH)_2\text{D}_3$), blunting intestinal calcium absorption and causing hypocalcemia. Phosphate retention and calcitriol deficiency stimulate chief cells to produce excess Parathyroid Hormone ($PTH$)—Secondary Hyperparathyroidism. High PTH increases bone resorption via $RANKL$, causing osteitis fibrosa cystica and osteomalacia, with metastatic vascular calcification ($\text{Ca} \times \text{P} > 55\,\text{mg}^2/\text{dL}^2$).

  • Role of ACEIs/ARBs: In CKD, hyperfiltration is driven by Angiotensin II-mediated efferent arteriolar constriction. ACEIs/ARBs selectively dilate the efferent arteriole, reducing intraglomerular capillary hydrostatic pressure ($P_{\text{gc}}$), which alleviates mechanical stress and reduces proteinuria. An acute serum creatinine increase up to $30\%$ is an acceptable functional hemodynamic adjustment, but patients must be monitored for hyperkalemia.

  • Systemic Complications: Cardiovascular disease is the leading cause of death ($> 50\%$ of mortality). Anemia occurs due to erythropoietin deficiency; dyslipidemia stems from downregulated lipoprotein lipase ($LPL$); insulin clearance falls (prolonging the half-life of insulin); and hypothalamic-pituitary-gonadal axis failure causes amenorrhea and erectile dysfunction.